Archives

Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression

B By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, improving patient throughput, and supporting a… Login to continue reading Login…

Read MoreAlar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression

Palindrome Technologies Achieves Milestone ISO/IEC 42001 Accreditation, Setting the Global Standard for AI Trustworthiness and Governance

B PRINCETON, N.J., April 6, 2026 /PRNewswire/ — As the adoption of Artificial Intelligence (AI) accelerates across the global economy, the demand for rigorous oversight… Login to continue reading Login…

Read MorePalindrome Technologies Achieves Milestone ISO/IEC 42001 Accreditation, Setting the Global Standard for AI Trustworthiness and Governance